Ym Biosciences Australia Pty Ltd.

Marcel Robert Kling

Christopher John Burns

John Thomas Feutrill

Tracy Leah Nero

David Gerard Bourke

Anthony Nicholas Cuzzupe

Andrew Frederick Wilks

Xianyong Bu

Jun Zeng

Herbert Rudolf Treutlein

Michelle Leanne Styles

The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

N-containing heterocyclic compounds

A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, Calkyl, O, S, SO, CO or CS and X, X, Xand Xare optionally substituted by 9 specific substituents or one can be nitrogen. Compositions comprising a carrier and at least one compound of formula (I) are also provided. Further provided are methods of treating tyrosine kinase-associated disease states by administering a compound of formula (I) and methods of suppressing the immune system of a subject by administering a compound of formula (I). 

Benzimidazoles as selective kinase inhibitors

A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating tyrosine kinase-associated disease states in a subject using a compound of formula (I) is also described. 

Nicotinamide-based kinase inhibitors

Growing community of inventors

Bentleigh, Australia

Marcel Robert Kling